戈沙妥珠单抗用于经大量预处理的铂耐药高级别浆液性卵巢癌
Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer.
作者信息
Greenman Michelle, Bellone Stefania, Demirkiran Cem, Max Philipp Hartwich Tobias, Santin Alessandro D
机构信息
Department of Obstetrics, Gynecology, and Reproductive Sciences Yale University School of Medicine, New Haven, CT 06520, USA.
出版信息
Gynecol Oncol Rep. 2024 Jul 13;54:101459. doi: 10.1016/j.gore.2024.101459. eCollection 2024 Aug.
BACKGROUND
Treatment of recurrent platinum-resistant high grade serous ovarian cancer (HGSOC) remains a challenge. Novel treatment options for recurrent disease are an unmet need.
CASE
A 69-year-old with recurrent, metastatic, platinum-resistant HGSOC overexpressing TROP2 experienced a significant response to the antibody-drug conjugate (ADC) sacituzumab govitecan after multiple failed lines of chemotherapy and targeted treatment. Following sacituzumab govitecan treatment she experienced a confirmed partial response as well as a return of CA-125 to baseline. Having now completed 8 cycles (ie, over 6 months of treatment), her disease continues to demonstrate a response to sacituzumab govitecan treatment. The ADC has been well tolerated at a dose of 10 mg/kg with no dose-limiting toxicity or need for dose reductions.
CONCLUSION
Sacituzumab govitecan may represent a treatment option for platinum-resistant/recurrent HGSOC that have previously failed prior lines of chemotherapy. Clinical trials with sacituzumab govitecan in platinum-resistant ovarian cancer patients are currently ongoing (https://classic.clinicaltrials.gov/ct2/show/NCT06028932).
背景
复发性铂耐药高级别浆液性卵巢癌（HGSOC）的治疗仍然是一项挑战。复发性疾病的新型治疗选择尚未得到满足。
病例
一名69岁的复发性、转移性、铂耐药HGSOC患者，TROP2过表达，在多线化疗和靶向治疗失败后，对抗体药物偶联物（ADC）戈沙妥珠单抗产生了显著反应。接受戈沙妥珠单抗治疗后，她出现了确认的部分缓解，CA-125也恢复到基线水平。目前已完成8个周期（即超过6个月的治疗），她的疾病继续对戈沙妥珠单抗治疗有反应。ADC以10mg/kg的剂量耐受性良好，没有剂量限制毒性或需要降低剂量。
结论
戈沙妥珠单抗可能是先前多线化疗失败的铂耐药/复发性HGSOC的一种治疗选择。目前正在进行戈沙妥珠单抗治疗铂耐药卵巢癌患者的临床试验（https://classic.clinicaltrials.gov/ct2/show/NCT06028932）。
Zotero 插件